Review



dpp4 (represented by sitagliptin mainly)  (AstraZeneca ltd)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    AstraZeneca ltd dpp4 (represented by sitagliptin mainly)
    Model parameters
    Dpp4 (Represented By Sitagliptin Mainly), supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dpp4+(represented+by+sitagliptin+mainly)/dpp+4+inhibitors/pmc10570198-45-12-20
    Average 90 stars, based on 1 article reviews
    dpp4 (represented by sitagliptin mainly) - by Bioz Stars, 2026-10
    90/100 stars

    Images

    1) Product Images from "A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus"

    Article Title: A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus

    Journal: Pharmacoeconomics

    doi: 10.1007/s40273-023-01268-5

    Model parameters
    Figure Legend Snippet: Model parameters

    Techniques Used: Comparison, Injection, Filtration, Infection, Cell Counting

    Cost-effectiveness and uncertainty results
    Figure Legend Snippet: Cost-effectiveness and uncertainty results

    Techniques Used: Comparison

    General characteristics of the studies
    Figure Legend Snippet: General characteristics of the studies

    Techniques Used: Comparison

    Related Articles

    Comparison:

    Article Title: A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus
    Article Snippet: Van der Linden, 2020 [ ] , Netherlands , Dapagliflozin ?? mg 1d vs. DPP4 (represented by sitagliptin mainly) , AstraZeneca , Societal , 40 , Fixed-time increment stochastic simulation model , Cardiff , None stated , Triple therapy or above , MET+SU.

    Injection:

    Article Title: A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus
    Article Snippet: Van der Linden, 2020 [ ] , Netherlands , Dapagliflozin ?? mg 1d vs. DPP4 (represented by sitagliptin mainly) , AstraZeneca , Societal , 40 , Fixed-time increment stochastic simulation model , Cardiff , None stated , Triple therapy or above , MET+SU.

    Filtration:

    Article Title: A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus
    Article Snippet: Van der Linden, 2020 [ ] , Netherlands , Dapagliflozin ?? mg 1d vs. DPP4 (represented by sitagliptin mainly) , AstraZeneca , Societal , 40 , Fixed-time increment stochastic simulation model , Cardiff , None stated , Triple therapy or above , MET+SU.

    Infection:

    Article Title: A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus
    Article Snippet: Van der Linden, 2020 [ ] , Netherlands , Dapagliflozin ?? mg 1d vs. DPP4 (represented by sitagliptin mainly) , AstraZeneca , Societal , 40 , Fixed-time increment stochastic simulation model , Cardiff , None stated , Triple therapy or above , MET+SU.

    Cell Counting:

    Article Title: A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus
    Article Snippet: Van der Linden, 2020 [ ] , Netherlands , Dapagliflozin ?? mg 1d vs. DPP4 (represented by sitagliptin mainly) , AstraZeneca , Societal , 40 , Fixed-time increment stochastic simulation model , Cardiff , None stated , Triple therapy or above , MET+SU.



    Similar Products

    dpp4 (represented by sitagliptin mainly)  (AstraZeneca ltd)
    90
    AstraZeneca ltd dpp4 (represented by sitagliptin mainly)
    Model parameters
    Dpp4 (Represented By Sitagliptin Mainly), supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dpp4+(represented+by+sitagliptin+mainly)/dpp+4+inhibitors/pmc10570198-45-12-20
    Average 90 stars, based on 1 article reviews
    dpp4 (represented by sitagliptin mainly) - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    dapagliflozin ?? mg 1d vs. dpp4 (represented by sitagliptin mainly)  (AstraZeneca ltd)
    90
    AstraZeneca ltd dapagliflozin ?? mg 1d vs. dpp4 (represented by sitagliptin mainly)
    Model parameters
    Dapagliflozin ?? Mg 1d Vs. Dpp4 (Represented By Sitagliptin Mainly), supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dpp4+(represented+by+sitagliptin+mainly)/dpp+4+inhibitors/pmc10570198-45-9-20
    Average 90 stars, based on 1 article reviews
    dapagliflozin ?? mg 1d vs. dpp4 (represented by sitagliptin mainly) - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Model parameters

    Journal: Pharmacoeconomics

    Article Title: A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus

    doi: 10.1007/s40273-023-01268-5

    Figure Lengend Snippet: Model parameters

    Article Snippet: Van der Linden, 2020 [ ] , Netherlands , Dapagliflozin ?? mg 1d vs. DPP4 (represented by sitagliptin mainly) , AstraZeneca , Societal , 40 , Fixed-time increment stochastic simulation model , Cardiff , None stated , Triple therapy or above , MET+SU.

    Techniques: Comparison, Injection, Filtration, Infection, Cell Counting

    Cost-effectiveness and uncertainty results

    Journal: Pharmacoeconomics

    Article Title: A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus

    doi: 10.1007/s40273-023-01268-5

    Figure Lengend Snippet: Cost-effectiveness and uncertainty results

    Article Snippet: Van der Linden, 2020 [ ] , Netherlands , Dapagliflozin ?? mg 1d vs. DPP4 (represented by sitagliptin mainly) , AstraZeneca , Societal , 40 , Fixed-time increment stochastic simulation model , Cardiff , None stated , Triple therapy or above , MET+SU.

    Techniques: Comparison

    General characteristics of the studies

    Journal: Pharmacoeconomics

    Article Title: A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus

    doi: 10.1007/s40273-023-01268-5

    Figure Lengend Snippet: General characteristics of the studies

    Article Snippet: Van der Linden, 2020 [ ] , Netherlands , Dapagliflozin ?? mg 1d vs. DPP4 (represented by sitagliptin mainly) , AstraZeneca , Societal , 40 , Fixed-time increment stochastic simulation model , Cardiff , None stated , Triple therapy or above , MET+SU.

    Techniques: Comparison

    Model parameters

    Journal: Pharmacoeconomics

    Article Title: A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus

    doi: 10.1007/s40273-023-01268-5

    Figure Lengend Snippet: Model parameters

    Article Snippet: Van der Linden, 2020 [ ] , Netherlands , Dapagliflozin ?? mg 1d vs. DPP4 (represented by sitagliptin mainly) , AstraZeneca , Societal , 40 , Fixed-time increment stochastic simulation model , Cardiff , None stated , Triple therapy or above , MET+SU.

    Techniques: Comparison, Injection, Filtration, Infection, Cell Counting

    Cost-effectiveness and uncertainty results

    Journal: Pharmacoeconomics

    Article Title: A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus

    doi: 10.1007/s40273-023-01268-5

    Figure Lengend Snippet: Cost-effectiveness and uncertainty results

    Article Snippet: Van der Linden, 2020 [ ] , Netherlands , Dapagliflozin ?? mg 1d vs. DPP4 (represented by sitagliptin mainly) , AstraZeneca , Societal , 40 , Fixed-time increment stochastic simulation model , Cardiff , None stated , Triple therapy or above , MET+SU.

    Techniques: Comparison

    General characteristics of the studies

    Journal: Pharmacoeconomics

    Article Title: A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus

    doi: 10.1007/s40273-023-01268-5

    Figure Lengend Snippet: General characteristics of the studies

    Article Snippet: Van der Linden, 2020 [ ] , Netherlands , Dapagliflozin ?? mg 1d vs. DPP4 (represented by sitagliptin mainly) , AstraZeneca , Societal , 40 , Fixed-time increment stochastic simulation model , Cardiff , None stated , Triple therapy or above , MET+SU.

    Techniques: Comparison